Jump to: navigation, search

{{Drugbox | Verifiedfields = changed | verifiedrevid = 464212885 | IUPAC_name = (RS)-N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide | image = Practolol structure.png | width = 250

| tradename =

| CASNo_Ref =  ☑Y | CAS_number_Ref =  ☑Y | CAS_number = 6673-35-4 | ATC_prefix = C07 | ATC_suffix = AB01 | PubChem = 4883 | IUPHAR_ligand = 555 | DrugBank_Ref =  ☑Y | DrugBank = DB01297 | ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 4715 | UNII_Ref =  ☑Y | UNII = SUG9176GRW | KEGG_Ref =  ☒N | KEGG = D05587 | ChEBI_Ref =  ☑Y | ChEBI = 258351 | ChEMBL_Ref =  ☑Y | ChEMBL = 6995

| C=14 | H=22 | N=2 | O=3 | molecular_weight = 266.336 g/mol | smiles = O=C(Nc1ccc(OCC(O)CNC(C)C)cc1)C | InChI = 1/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17) | InChIKey = DURULFYMVIFBIR-UHFFFAOYAT | StdInChI_Ref =  ☑Y | StdInChI = 1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17) | StdInChIKey_Ref =  ☑Y | StdInChIKey = DURULFYMVIFBIR-UHFFFAOYSA-N }}

WikiDoc Resources for Practolol


Most recent articles on Practolol

Most cited articles on Practolol

Review articles on Practolol

Articles on Practolol in N Eng J Med, Lancet, BMJ


Powerpoint slides on Practolol

Images of Practolol

Photos of Practolol

Podcasts & MP3s on Practolol

Videos on Practolol

Evidence Based Medicine

Cochrane Collaboration on Practolol

Bandolier on Practolol

TRIP on Practolol

Clinical Trials

Ongoing Trials on Practolol at Clinical

Trial results on Practolol

Clinical Trials on Practolol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Practolol

NICE Guidance on Practolol


FDA on Practolol

CDC on Practolol


Books on Practolol


Practolol in the news

Be alerted to news on Practolol

News trends on Practolol


Blogs on Practolol


Definitions of Practolol

Patient Resources / Community

Patient resources on Practolol

Discussion groups on Practolol

Patient Handouts on Practolol

Directions to Hospitals Treating Practolol

Risk calculators and risk factors for Practolol

Healthcare Provider Resources

Symptoms of Practolol

Causes & Risk Factors for Practolol

Diagnostic studies for Practolol

Treatment of Practolol

Continuing Medical Education (CME)

CME Programs on Practolol


Practolol en Espanol

Practolol en Francais


Practolol in the Marketplace

Patents on Practolol

Experimental / Informatics

List of terms related to Practolol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Practolol (Eraldin, Dalzic, Praktol, Cardiol, Pralon, Cordialina, Eraldina, Teranol) is a selective beta blocker that has been used in the emergency treatment of cardiac arrhythmias. Practolol is no longer used as it is highly toxic despite the similarity of its chemical formula to propranolol. After its introduction, keratoconjunctivitis sicca, conjunctival scarring, fibrosis, metaplasia, and shrinkage developed in 27 patients as an adverse reaction to practolol. Rashes, nasal and mucosal ulceration, fibrous or plastic peritonitis, pleurisy, cochlear damage, and secretory otitis media also occurred in some cases. Three patients suffered profound visual loss though most retained good vision. Symptoms and signs improved on withdrawal of the drug, but reduction of tear secretion persisted in most patients. (British Medical Journal, March 15, 1975)

Side Effects

Side effects are similar to those of other beta blockers, such as bronchoconstriction, cardiac failure, cold extremities, fatigue and depression, hypoglycaemia.[1]

Furthermore, chronic use of practolol may cause oculomucocutaneous syndrome,[1] a severe syndrome whose signs include conjunctivitis sicca and psoriasiform rashes, otitis and sclerosing serositis. This syndrome has not been observed with other such beta blockers.[2]


This drug has been withdrawn from the market in India due to Oculomucocutaneous Syndrome.[3]

External Links

Scientific information / studies
General information


  1. 1.0 1.1 Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-06911-5.
  2. > Nadolol Retrieved on July, 2010.
  3. "Drugs banned in India". Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Retrieved 2013-09-17.